Parkinson’s is a
neurodegenerative disease characterized by abnormal misfolded protein known as
alpha-synuclein. It is one of a group of disorders known as synucleinopathies. Accurate diagnosis of
any of these diseases, especially in the early stages, is challenging which can
result in misdiagnosis.
CND Life Sciences has developed
a new diagnostic tool called the Syn-One Test™ that accurately detects and
visualizes abnormal alpha-synuclein in cutaneous nerve fibers. The synucleinopathies encompass a
group of neurodegenerative diseases that include:
· Parkinson’s disease
· Dementia with Lewy bodies
· Multiple system atrophy
· Pure autonomic failure
· REM sleep behavior disorder
An abnormal test that identifies phosphorylated
synuclein (p-syn) within cutaneous nerves is highly specific for a diagnosis of
a synucleinopathy, but cannot distinguish between the synucleinopathies.
Physicians should use the results of the Syn-One Test along with other clinical
features to help make a more specific diagnosis.to help avoid
sub-optimal care recommendations and poor outcomes.
Personally, I want to know what I am dealing with
so I can seek appropriate treatment and make informed choices for my
future. While this is not an endorsement, it is a recommendation for
Movement disorder doctors, Palliative care teams, PwP’s, care partners and
their families to research this new development. For further
information, visit CND LIfe Sciences
- Home of the Syn-One Test™.
